This presentation was part of the 2021 clinical symposia, Radiotherapy for Benign Conditions. See Dr. Steenbakker’s presentation below from the second session, Radiotherapy for Hyperproliferative Disorders.
XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.
Xstrahl’s XBeam has received FDA 510(k) Clearance for Use in the U.S. The XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. Explore how this innovation enhances orthovoltage superficial radiotherapy (SRT) and electronic brachytherapy (eBt). With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide.
